Bio-Techne (TECH) CEO nets shares after stock option exercise
Rhea-AI Filing Summary
Bio-Techne Corp Chief Executive Officer Kim Kelderman reported compensation-related equity activity, not open-market trading. On April 22, 2026, Kelderman exercised stock options to acquire 11,344 shares of Bio-Techne common stock, while 1,363 shares were disposed of to cover tax obligations at $58.58 per share. This left Kelderman with 63,058 common shares held directly after these transactions.
The filing also lists substantial remaining equity incentives, including multiple tranches of stock options and restricted stock units tied to vesting schedules and performance goals, with option exercise prices ranging from $47.60 to $120.46 and expirations extending to August 15, 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 9,981 shares
Net Buy
19 txns
Insider
Kelderman Kim
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 11,344 | $0.00 | $0.00 |
| Exercise | Common Stock | 11,344 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,363 | $58.58 | $80K |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 203,360 shares (Direct);
Common Stock — 63,058 shares (Direct);
Stock Options (Right to Buy) — 307,975 shares (Direct);
Performance Restricted Stock Units — 140,265 shares (Direct);
Performance Stock Options (Right to Buy) — 49,826 shares (Direct);
Restricted Stock Units — 52,441 shares (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F3. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F4. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- F5. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- F6. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- F7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F8. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
- F9. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- F10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
- F12. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Key Figures
Options exercised: 11,344 shares
Tax-withheld shares: 1,363 shares
Direct common shares after transactions: 63,058 shares
+4 more
7 metrics
Options exercised
11,344 shares
Stock option exercise into common stock on April 22, 2026
Tax-withheld shares
1,363 shares
Shares delivered for tax obligations at $58.58 per share
Direct common shares after transactions
63,058 shares
Direct ownership of Bio-Techne common stock following Form 4 activity
Exercised option strike price
$47.60/share
Exercise price of stock option converted into 11,344 common shares
Largest remaining option block
115,724 shares
Stock option (right to buy) at $66.97, expiring August 5, 2027
Highest option strike price
$120.46/share
Stock option (right to buy) expiring August 6, 2028
Latest option expiration
August 15, 2035
Stock options (right to buy) on 90,441 underlying shares
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, Performance Stock Options, tax-withholding disposition, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Vests in full or in part on 8/15/2026 if certain performance goals are achieved."
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Performance Stock Options financial
"Performance Stock Options (Right to Buy) with exercise prices such as 68.5400 and 84.6100 per share."
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities is described as a tax-withholding disposition."
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative security financial
"Exercise or conversion of derivative security is noted for the stock option transaction code M."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did BIO-TECHNE (TECH) CEO Kim Kelderman report in this Form 4?
Kim Kelderman reported compensation-related equity movements, not open-market trades. He exercised stock options for 11,344 Bio-Techne common shares and had 1,363 shares withheld to cover tax obligations, updating his direct common stock holdings and derivative award balances.
What does the tax-withholding disposition mean in the BIO-TECHNE (TECH) Form 4?
The filing shows 1,363 Bio-Techne common shares disposed of at $58.58 per share for tax withholding. This means shares were delivered to satisfy tax obligations related to equity awards, rather than sold in an open-market transaction directed by the CEO.
What equity awards remain outstanding for the BIO-TECHNE (TECH) CEO?
The filing lists multiple remaining awards, including stock options and performance-based grants. These have exercise prices between $47.60 and $120.46 per share and expiration dates running through August 15, 2035, along with restricted stock units and performance restricted stock units.
Are the BIO-TECHNE (TECH) CEO’s reported transactions open-market buys or sells?
The reported events are not open-market trades. They include an option exercise, converting derivative rights into 11,344 common shares, and a 1,363-share tax-withholding disposition, where shares are used to pay taxes on equity compensation instead of being voluntarily sold in the market.